Immunotherapy Focus Takis specializes in cancer immunotherapy and immune system instruction to recognize tumors, presenting a clear opportunity to position partnerships around personalized therapy development, biomarker-driven diagnostic tools, and in vivo gene delivery collaborations.

Gene Delivery Expertise With over a decade of experience in gene-electro-transfer and in vivo nucleic acid delivery, Takis can be a prime collaborator for contract research, co-development of delivery platforms, and potential technology licensing to accelerate preclinical programs.

Biomarker & Diagnostics Active work on biomarker discovery and molecular diagnostic test development creates openings for joint development programs, companion diagnostics partnerships, and revenue opportunities from diagnostic assay services.

Strategic Partnerships Takis positions itself as an efficient, fast, and low-cost partner for academic and industrial projects, suggesting a target to approach with collaborative research, sponsored studies, and fee-for-service engagements.

Financial & Growth Potential Revenue in the lower-to-mid tens of millions with a lean team size indicates room for scalable collaboration models (milestone-based programs, licensing wins, and co-funded trials) to expand market reach with larger biotech players.